EVALUATION AND LONG-TERM FOLLOW-UP OF HBSAG-POSITIVE BLOOD DONORS

1970年至年间确认的乙肝表面抗原(HBs)阳性献血者 目前将被纳入以确定以下各项的长期后果 无症状献血者中的乙肝病毒感染。捐赠者 将由华盛顿红十字会和卫生部确定 美国国立卫生研究院输血医学部。重点将放在找到的捐赠者身上 5年或以上乙肝表面抗原阳性。研究的主要目标将是 确定无症状的乙肝表面抗原阳性献血者有多大比例 慢性肝炎的已开发证据以及可能有多大比例 演变为肝细胞癌(HCC)。这项研究的一个主要主旨 甲胎蛋白的检测将是肝细胞癌的早期发现。 早期的肝细胞癌似乎可以接受手术干预。捐赠者被发现患有 根据一项单独的条款，肝癌将被转介给NIH外科服务 协议。一旦登记，捐赠者将被跟踪至少5年。

Hepatitis B Surface Antigen (HBsAg) positive donors identified from 1970 to the present will be enrolled to determine the long-term consequences of Hepatitis B Virus (HBV) infection in asymptomatic blood donors. Donors will be identified by the Washington Red Cross and the Department of Transfusion Medicine, NIH. Emphasis will be placed on those donors found HBsAg positive 5 or more years ago. The primary study goals will be to determine what proportion of asymptomatic HBsAg positive donors have developed evidence of chronic hepatitis and what proportion may have evolved into hepatocellular carcinoma (HCC). A major thrust of the study will be the early detection of HCC by measurement of alphafetoprotein. Early HCC appears amenable to surgical intervention. Donors found to have HCC will be referred to the NIH Surgical Service under a separate protocol. Once enrolled, donors will be followed for at least 5 years.